(MCK) McKesson - Overview
Stock: Pharmaceuticals, Medical Supplies, Technology, Distribution
| Risk 5d forecast | |
|---|---|
| Volatility | 23.9% |
| Relative Tail Risk | -9.86% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.55 |
| Alpha | 49.01 |
| Character TTM | |
|---|---|
| Beta | 0.272 |
| Beta Downside | 0.284 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.91% |
| CAGR/Max DD | 1.87 |
EPS (Earnings per Share)
Revenue
Description: MCK McKesson March 04, 2026
McKesson Corporation (MCK) is a healthcare services company operating in the U.S. and internationally. The company functions across four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International.
The U.S. Pharmaceutical segment focuses on distributing a wide range of pharmaceutical drugs, including branded, generic, and specialty medications. This segment also provides support services like practice management and technology solutions to healthcare providers. The pharmaceutical distribution sector is characterized by high volume and complex supply chains.
The RxTS segment offers solutions to biopharma and life sciences partners, aiming to improve patient access to medication. This includes services such as medication access and affordability programs, prescription decision support, and electronic prior authorization. This segment operates at the intersection of healthcare technology and pharmaceutical access.
Medical-Surgical Solutions provides distribution, logistics, and maintenance services for medical-surgical supplies to various healthcare providers, including physician offices and hospitals. This segment is critical for maintaining the operational efficiency of healthcare facilities.
The International segment delivers medicines, supplies, and IT solutions to retail pharmacies, hospitals, and other institutions globally, along with logistics and distribution services for manufacturers. The global pharmaceutical distribution market is highly regulated and fragmented.
For more detailed financial and operational insights, consider exploring ValueRays comprehensive company profiles.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 4.34b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 9.69 > 1.0 |
| NWC/Revenue: -2.12% < 20% (prev -1.98%; Δ -0.14% < -1%) |
| CFO/TA 0.12 > 3% & CFO 10.48b > Net Income 4.34b |
| Net Debt (5.67b) to EBITDA (6.47b): 0.88 < 3 |
| Current Ratio: 0.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (123.7m) vs 12m ago -2.29% < -2% |
| Gross Margin: 3.37% > 18% (prev 0.04%; Δ 333.7% > 0.5%) |
| Asset Turnover: 512.6% > 50% (prev 484.8%; Δ 27.82% > 0%) |
| Interest Coverage Ratio: 25.04 > 6 (EBITDA TTM 6.47b / Interest Expense TTM 231.0m) |
Altman Z'' 0.89
| A: -0.10 (Total Current Assets 59.70b - Total Current Liabilities 68.13b) / Total Assets 84.19b |
| B: 0.25 (Retained Earnings 20.71b / Total Assets 84.19b) |
| C: 0.07 (EBIT TTM 5.78b / Avg Total Assets 77.64b) |
| D: 0.24 (Book Value of Equity 19.81b / Total Liabilities 84.29b) |
| Altman-Z'' Score: 0.89 = B |
Beneish M -2.88
| DSRI: 0.95 (Receivables 28.21b/25.83b, Revenue 397.96b/344.58b) |
| GMI: 1.10 (GM 3.37% / 3.71%) |
| AQI: 1.10 (AQ_t 0.24 / AQ_t-1 0.21) |
| SGI: 1.15 (Revenue 397.96b / 344.58b) |
| TATA: -0.07 (NI 4.34b - CFO 10.48b) / TA 84.19b) |
| Beneish M-Score: -2.88 (Cap -4..+1) = A |
What is the price of MCK shares?
Over the past week, the price has changed by +4.09%, over one month by +17.08%, over three months by +23.73% and over the past year by +55.09%.
Is MCK a buy, sell or hold?
- StrongBuy: 10
- Buy: 3
- Hold: 3
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the MCK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 980.4 | -1.5% |
| Analysts Target Price | 980.4 | -1.5% |
MCK Fundamental Data Overview February 28, 2026
P/E Forward = 19.802
P/S = 0.3022
P/B = 5.0435
P/EG = 1.1192
Revenue TTM = 397.96b USD
EBIT TTM = 5.78b USD
EBITDA TTM = 6.47b USD
Long Term Debt = 5.42b USD (from longTermDebt, last quarter)
Short Term Debt = 1.42b USD (from shortTermDebt, last quarter)
Debt = 8.62b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.67b USD (from netDebt column, last quarter)
Enterprise Value = 125.94b USD (120.27b + Debt 8.62b - CCE 2.96b)
Interest Coverage Ratio = 25.04 (Ebit TTM 5.78b / Interest Expense TTM 231.0m)
EV/FCF = 12.47x (Enterprise Value 125.94b / FCF TTM 10.10b)
FCF Yield = 8.02% (FCF TTM 10.10b / Enterprise Value 125.94b)
FCF Margin = 2.54% (FCF TTM 10.10b / Revenue TTM 397.96b)
Net Margin = 1.09% (Net Income TTM 4.34b / Revenue TTM 397.96b)
Gross Margin = 3.37% ((Revenue TTM 397.96b - Cost of Revenue TTM 384.53b) / Revenue TTM)
Gross Margin QoQ = 3.47% (prev 3.43%)
Tobins Q-Ratio = 1.50 (Enterprise Value 125.94b / Total Assets 84.19b)
Interest Expense / Debt = 0.73% (Interest Expense 63.0m / Debt 8.62b)
Taxrate = 23.31% (380.0m / 1.63b)
NOPAT = 4.44b (EBIT 5.78b * (1 - 23.31%))
Current Ratio = 0.88 (Total Current Assets 59.70b / Total Current Liabilities 68.13b)
Debt / Equity = -6.64 (negative equity) (Debt 8.62b / totalStockholderEquity, last quarter -1.30b)
Debt / EBITDA = 0.88 (Net Debt 5.67b / EBITDA 6.47b)
Debt / FCF = 0.56 (Net Debt 5.67b / FCF TTM 10.10b)
Total Stockholder Equity = -1.77b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.59% (Net Income 4.34b / Total Assets 84.19b)
RoE = -245.3% (negative equity) (Net Income TTM 4.34b / Total Stockholder Equity -1.77b)
RoCE = 158.2% (EBIT 5.78b / Capital Employed (Equity -1.77b + L.T.Debt 5.42b))
RoIC = 85.84% (NOPAT 4.44b / Invested Capital 5.17b)
WACC = 6.49% (E(120.27b)/V(128.90b) * Re(6.92%) + D(8.62b)/V(128.90b) * Rd(0.73%) * (1-Tc(0.23)))
Discount Rate = 6.92% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -3.67%
[DCF] Terminal Value 84.37% ; FCFF base≈6.71b ; Y1≈7.00b ; Y5≈8.06b
[DCF] Fair Price = 1583 (EV 199.62b - Net Debt 5.67b = Equity 193.95b / Shares 122.5m; r=6.49% [WACC]; 5y FCF grow 4.56% → 2.90% )
EPS Correlation: 85.51 | EPS CAGR: 13.39% | SUE: 0.44 | # QB: 0
Revenue Correlation: 96.68 | Revenue CAGR: 13.47% | SUE: 0.08 | # QB: 0
EPS next Quarter (2026-06-30): EPS=9.72 | Chg7d=-0.020 | Chg30d=-0.039 | Revisions Net=-3 | Analysts=7
EPS next Year (2027-03-31): EPS=44.22 | Chg7d=+0.014 | Chg30d=+0.417 | Revisions Net=+15 | Growth EPS=+13.3% | Growth Revenue=+8.2%
[Analyst] Revisions Ratio: -0.43 (2 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.4% (Discount Rate 7.9% - Earnings Yield 3.6%)
[Growth] Growth Spread = +3.5% (Analyst 7.9% - Implied 4.4%)